Aug 25,2023

ChatGPT Shows Limited Ability to Recommend Guidelines-Based Cancer Treatments

With ChatGPT now at patients’ fingertips, researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, assessed how consistently the artificial intelligence chatbot provides recommendations for cancer treatment that align with National Comprehensive Cancer Network (NCCN) guidelines. Their findings, published in JAMA Oncology, show that in approximately one-third of cases, ChatGPT 3.5 provided an inappropriate (“non-concordant”) recommendation, highlighting the need for awareness of the technology’s limitations.

CLINICAL STUDY

#chatbot

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 23,2023

How real-world data is enhancing our understanding of lung cancer recurrence

A collaborative team from COTA and AstraZeneca used curated RWD to investigate factors affecting disease-free survival and recurrence patterns in early-stage non-small cell lung cancer (NSCLC) patients. The researchers examined patterns of care, disease-free survival, and patient characteristics using real-world data from over 700 early-stage NSCLC patients diagnosed between 2013 and 2018. They found that patients with more advanced disease stages, genetic mutations (EGFRm positive), and those who only had surgical resection had shorter disease-free survival times. Distant/metastatic recurrence was common among all patients. The study confirmed that disease stage at diagnosis influences disease-free survival and supported the idea that adjuvant therapies improve disease-free survival compared to surgery alone.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Aug 25,2023

Jasper Health and Covet Health Form Partnership

Jasper Health, a comprehensive cancer care benefits solution, and Covet Health, a digital health benefit solution provider and innovative third-party administration platform, have formed a partnership. Covet Health will start offering Jasper’s Cancer Care Companion to employer clients, including high touch guidance and cancer care support for employees and their caregivers. “This partnership aligns seamlessly with our mission to provide employees with the psychosocial support and digital planning tools they need to feel more supported and make informed decisions about their cancer care.” said Adam Pellegrini, Co-Founder and CEO at Jasper Health.

COLLABORATION PARTNERSHIP

#institution

#rpm

#coaching

View Analyst & Ambassador Comments
Go to original news
Aug 22,2023

UK study prompts call for MRI screening for prostate cancer

A UK study has suggested that a 10-minute MRI scan is more effective at detecting prostate cancer than testing for blood levels of the biomarker PSA, picking up serious cases that would not be spotted using PSA alone. There is currently no UK-wide screening programme for prostate cancer because the PSA test is not reliable, although men aged over 50 can request one if desired. The analysis revealed that out of 29 who were found to have serious prostate cancer, 15 had a low PSA score, which would mean they were not referred for further clinical investigation. Three men were diagnosed with low-risk cancer that did not require treatment.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jul 27,2023

Blackford and Lunit Inc announce partnership to enhance chest and breast AI solution offering

Blackford, the strategic imaging AI platform and solutions provider, and Lunit Inc, a chest Xray and mammography AI provider announce a partnership to make Lunit INSIGHT CXR, INSIGHT CXR Triage and INSIGHT MMG available on the Blackford Platform. Lunit’s AI applications will enable Blackford customers to detect cancer on chest radiographs and mammograms.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 22,2023

Veracyte Announces that Findings Published in JCO Precision Oncology to Predict Treatment Response in Recurrent Prostate Cancer

Veracyte announced that new data published in JCO Precision Oncology suggest that gene expression signatures derived from the company’s Decipher Genomics Resource for Intelligent Discovery (GRID) database may help advance understanding of the genomic drivers impacting patient response to treatment for recurrent prostate cancer. Researchers conducted a retrospective analysis using the Decipher GRID database to determine whether specific genomic signatures could help predict which patients would benefit from the aggressive therapy regimen, and which may require additional or alternative care. The findings, from the Phase 2 STREAM study, suggest the potential to use transcriptomic signatures to identify patients in this setting who may benefit from more intensive salvage therapy as well as those who may need alternative care such as chemotherapy.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 22,2023

Tempus Welcomes UNC Lineberger Comprehensive Cancer Center to Tempus+ Community

Tempus, a leader in artificial intelligence and precision medicine, today announced that the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes over 30 medical centers that are leveraging the program to advance its research. Tempus+ is creating a sustainable and secure infrastructure to collect and analyze the data required to foster research that can inform the future of clinical care. Researchers at UNC Lineberger now have access to Tempus’ library of more than six million de-identified research records through the company’s data analytics platform, Lens, to identify patterns and insights, define and test their hypotheses, and eventually investigate and potentially publish their research.

COLLABORATION PARTNERSHIP

#institution

#rwd

View Analyst & Ambassador Comments
Go to original news
Aug 16,2023

Verily, OneOncology Create Clinical Trial Partnership to Feature Use of SignalPath Across Practices

Practices in the OneOncology Research Network (OneR) will have access to SignalPath, a first-of-its-kind clinical trial management software platform, as part of a broader strategic partnership between the community oncology network and Verily, officials of the groups announced today. Use of SignalPath will improve efficiency, ease compliance, boost enrollment, and ensure financial success in clinical trials, leaders of the partnership told The American Journal of Managed Care® in interviews. According to a statement, the partnership seeks to bring new research opportunities to community oncology practices, where pharmaceutical companies are looking to enroll patients who reflect the broader population of those who have cancer.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 22,2023

Value-based oncology platform Thyme Care clinches $60M to expand in new markets

Thyme Care, a value-based oncology platform, has raised $60 million in a series B round. The round was co-led by Town Hall Ventures and Foresite Capital with participation from existing investors Andreessen Horowitz Bio + Health, AlleyCorp, Casdin Capital and Frist Cressey Ventures. The funding will be used to accelerate partnerships in new markets and expand its cancer care support services. Thyme Care also plans to broaden its roster of oncology and healthcare experts and announce additional partnerships in the coming months. The latest capital brings the company’s total raised to more than $80 million. Thyme Care combines tech with high-touch patient care to support care journeys. Powered by a team of nurse practitioners, oncology nurses and resource specialists, the company aims to help members better understand their diagnosis, manage and address symptoms and quickly connect them to care with its platform, Thyme Box.

FUNDING SERIES B

#virtual care

View Analyst & Ambassador Comments
Go to original news
Mar 30,2023

Stilla Technologies and Atila BioSystems to Co-Develop High-Plex Digital PCR Kits for Oncology

Stilla Technologies and Atila BioSystems today announced an agreement to market digital PCR kits and assays produced by Atila BioSystems for use on the naica® system (Stilla Technologies). The digital PCR kits, optimized specifically for use with the 6-color naica® system, will be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples taken from patients with high-occurring cancer indications such as breast, lung, melanoma, prostate, and colorectal cancers.

COLLABORATION PARTNERSHIP

#r&d

#self-tests

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY